SUBSCRIBE
SUBSCRIBE
American Society of Clinical Oncology

ASCO

Bristol-Myers Squibb's Stock Topples as Kidney Cancer Drug Flunks Phase III Study
Drug Development
Bristol-Myers Squibb Loses $4.3 Billion in Market Value After ASCO Update
June 7, 2017
 · 
3 min read
Load More
PRESS RELEASES
Press Releases
Diakonos Oncology Shares Updated DOC1021 GBM Survival Data and Unveils Melanoma Clinical Study at ASCO 2026
June 7, 2026
 · 
6 min read
Press Releases
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
June 4, 2026
 · 
7 min read
Press Releases
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
June 4, 2026
 · 
7 min read
Press Releases
Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
June 3, 2026
 · 
10 min read
Press Releases
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare’s Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
June 3, 2026
 · 
2 min read
Press Releases
Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
June 3, 2026
 · 
4 min read
Press Releases
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
June 3, 2026
 · 
13 min read
Press Releases
Stelexis BioSciences Announces Positive Phase 1 Data for Eganelisib in Relapsed/Refractory AML and Higher-Risk MDS in an Oral Presentation at ASCO 2026
June 3, 2026
 · 
6 min read
Press Releases
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
June 2, 2026
 · 
9 min read
Press Releases
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
June 2, 2026
 · 
6 min read
Press Releases
SEED Therapeutics Highlights Clinical Advancement and Broad Oncology Potential of ST-01156, an RBM39 Molecular Glue Degrader in First-in-Human in Phase 1 Studies, at ASCO 2026
June 2, 2026
 · 
7 min read
Press Releases
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
June 2, 2026
 · 
5 min read
Press Releases
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
June 2, 2026
 · 
8 min read
Press Releases
Fulgent Presents Updated FID-007 Data at ASCO 2026
June 2, 2026
 · 
4 min read
Press Releases
Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting
June 2, 2026
 · 
5 min read
Press Releases
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
June 2, 2026
 · 
11 min read
Press Releases
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
June 2, 2026
 · 
6 min read
Press Releases
Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026
June 2, 2026
 · 
6 min read
Press Releases
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
June 1, 2026
 · 
30 min read
Press Releases
Paradigm Health Implements New Clinical Trial Solution to Support Observational Study Presented at ASCO
June 1, 2026
 · 
5 min read
Load More